Sarcoidosis — Research Summary
Printed from RareWays (rareways.com.au) on 10 September 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.
Lhote Raphael et al. — Pulmonology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42339517/
- 2.
Monitoring the safety of the adjuvanted human papillomavirus vaccine HPV-16/18-AS04 in association with pregnancy and potential immune-related diseases in China: A retrospective observational cohort study.
Yang Junting et al. — Human vaccines & immunotherapeutics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42348585/
- 3.
scRNA-seq based gene and cell dynamics behind the formation of the non-caseating granulomas.
Singh Neha et al. — Computational biology and chemistry (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42001827/
- 4.
Targeting CXCR6 suppresses granuloma formation and pulmonary fibrosis through inhibiting Th17 responses in sarcoidosis.
Han Yueyin et al. — International immunopharmacology (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42143504/
- 5.
Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?
Pericao Ana et al. — Current opinion in pulmonary medicine (3 July 2026)
https://pubmed.ncbi.nlm.nih.gov/42396691/
Clinical Trials — Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia
Active (not recruiting) — Na — Western Sydney Local Health District
https://clinicaltrials.gov/study/NCT05524077
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Sarcoidosis
Sarcoidosis is a chronic inflammatory disease characterised by the formation of granulomas that can affect any organ but most commonly the lungs and lymph nodes. Its cause remains unknown. Many patients experience spontaneous remission, but a significant minority develop progressive organ damage requiring long-term treatment.
Most Recent Research
OBJECTIVES: Evidence supporting an occupational hypothesis for sarcoidosis remains limited. The hypothesis of the present study was that some occupational exposures might be more prevalent among sarcoidosis patients than in the French population. METHODS: A cross-sectional observational study design was used to collect occupational data from patients enrolled in the Epidemiology ofSarcoidosis (EpiSarc) cohort study with documented sarcoidosis. The data were initiallyclassified according to the occupational classification of the French National Institute ofStatistics and Economic Studies and then compared to employment data fromthe French population for the reference year 2016. RESULTS: Among the 1,512 sarcoidosis patients included, occupational data were avail- able for 1,177 patients (78%). Of these, 1,086 (92%) were employed at time of sarcoidosis diagnosis. Notably, manual workers were significantly overrepresented compared to the general French population (40% versus 20%, p < 0.0001). Among the 471 manual workers, the distribution of occupations was as follows: construction workers (n = 165, 35%), domestic helpers and cleaners (n = 109, 23%), transportation and handling workers (n = 82, 17.5%), manufacturing labourers and industrial operators (n = 67, 14%), textile indus- try workers (n = 25, 5.5%), and other occupations (n = 23, 5%). The frequency of patients with manual working occupations varied depending on the organ involvement, being the highest in patients with lung involvement. CONCLUSION: We found that manual workers occupations with exposure to various environmental hazards that may trigger inflammation promoting an abnormal granulomatous immune response, including dust, were associated with sarcoidosis.
Common Questions
What is Sarcoidosis?
Sarcoidosis is a chronic inflammatory disease characterised by the formation of granulomas that can affect any organ but most commonly the lungs and lymph nodes. Its cause remains unknown. Many patients experience spontaneous remission, but a significant minority develop progressive organ damage requiring long-term treatment.
How many clinical trials are available for Sarcoidosis?
RareWays currently indexes 223 clinical trials for Sarcoidosis, of which 48 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Sarcoidosis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Sarcoidosis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.